Asymptomatic dapsone‐induced agranulocytosis in a patient with chronic spontaneous urticaria

Milkova, Linda; Hallermann, Christine; Simon, Jan‐Christoph; Treudler, Regina

doi:10.1111/ddg.12320

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was an earlier report of dapsone‐associated agranulocytosis and severe anemia in a patient with leukocytoclastic vasculitis . Similarly, agranulocytosis was also reported in patients with giant cell (temporal) arteritis , dermatitis herpetiformis , granuloma annulare , and urticaria . Several cases of dapsone‐induced agranulocytosis, hemolytic anemia, neutropenia, thrombocytopenia, septic shock, and hypersensitivity have also been described .…”

Section: Discussionmentioning

confidence: 87%

Dapsone‐induced agranulocytosis—possible involvement of low‐activity N‐acetyltransferase 2

Potočnjak

Likić

Šimić

et al. 2017

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Dapsone-induced agranulocytosis is a rare but potentially fatal adverse drug reaction (ADR). A 45-year-old male Caucasian patient developed agranulocytosis caused by dapsone (diamino-diphenyl sulfone), which he was prescribed for leukocytoclastic vasculitis. Patient's treatment consisted of termination of dapsone, antibiotic therapy, and granulocyte colony-stimulating factor leading to prompt improvement of symptoms and normalization of laboratory blood values. Diagnostic evaluation revealed methemoglobinemia and excluded glucose-6-phosphate dehydrogenase deficiency. Pharmacogenetics testing showed that he was a carrier of NAT2 *5/*6 genotype, predisposing to low activity of the N-acetyltransferase 2 enzyme. This was the first and only ADR to dapsone reported in Croatia. In total, there have been 73 ADR to dapsone recorded worldwide, including only four cases of agranulocytosis.

show abstract

Section: Discussionmentioning

confidence: 87%